Union Commerce and Industry Minister Piyush Goyal on Friday, June 12, 2026, began his visit to Switzerland by co-chairing a meeting with Helene Budliger Artieda, State Secretary for Economic Affairs of Switzerland, and representatives of leading Swiss pharmaceutical and biotechnology companies, signalling a push to convert treaty commitments into concrete investment flows into India's life sciences sector.

Context

Goyal posted on X that the discussions 'focused on strengthening collaboration in research and innovation, as well as on new investment opportunities for Swiss pharma companies in India's rapidly growing healthcare and life sciences sector.' The meeting, co-chaired with Artieda of the Swiss State Secretariat for Economic Affairs (SECO), brought together senior industry representatives from Switzerland's globally prominent pharmaceutical and biotechnology sector.

Switzerland is among India's top sources of foreign direct investment, with major Swiss corporations active across pharmaceuticals, precision engineering, and financial services. The bilateral relationship has been institutionalised through regular meetings of the India-Switzerland Joint Economic Commission, a forum that dates to the 1980s.

Policy Backdrop

The visit comes on the back of the landmark India-EFTA Trade and Economic Partnership Agreement (TEPA), signed in 2024, which included specific provisions for Swiss investment in India's life sciences sector and mutual recognition of regulatory standards. Switzerland is a member of the European Free Trade Association (EFTA), and the TEPA represented a significant milestone in India's outreach to European economic partners.

India has also been actively promoting its Production Linked Incentive (PLI) scheme for pharmaceuticals, launched in 2021, which offers financial incentives to attract global investment and scale up domestic manufacturing capacity in bulk drugs and formulations. These policy instruments form the backdrop against which Goyal's Switzerland engagement is taking place.

Stakeholders and Impact

Swiss pharmaceutical and biotechnology firms stand at the centre of this engagement. Switzerland is home to some of the world's largest R&D-intensive pharma corporations, and their investment interest in India aligns with New Delhi's ambition to position the country as a global hub for high-value drug manufacturing and biotech innovation.

Indian biotech firms and domestic pharmaceutical clusters — particularly those in Hyderabad, Pune, and Ahmedabad — are potential beneficiaries of any technology partnerships or greenfield investments that may emerge from such bilateral dialogue. The PLI scheme and the TEPA framework together offer Swiss companies a structured entry point into India's rapidly expanding healthcare market.

What's Next

Observers will watch for follow-up announcements on specific Swiss investment projects in Indian pharma clusters and any progress on the next meeting of the India-Switzerland Joint Economic Commission. India has intensified outreach to European investors since the EFTA agreement, seeking long-term capital and technology partnerships in high-value sectors. Goyal's Switzerland visit is expected to continue with further engagements aimed at translating the TEPA's commitments into a concrete project pipeline and addressing regulatory or intellectual property concerns raised by prospective investors.